Prevention & lipidsMeta-analysis

PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations

Eur J Prev CardiolPublished

  • Mendelian randomisation study (phenome-wide genetic association analysis)
  • prospective biobank
  • genetic score of 3 PCSK9 variants
  • replication with UK Biobank meta-analysis

Authors' conclusion

The LDL-C-lowering PCSK9 genetic variants are associated with lower risk of subclinical and clinical atherosclerotic vascular disease but higher risks of respiratory diseases.

Study context

Population
Participants of the China Kadoorie Biobank (replication with UK Biobank)over 100,000 (lay summary)
Comparison
PCSK9 genetic score

Pooled result

As reported in the abstract

PCSK9-GS associations, per 1 SD lower LDL-C
PCSK9-GSOdds ratio (95% CI)P value
carotid plaque, n = 8340 cases
0.61(0.45–0.83)
P = 0.0015
major occlusive vascular events, n = 15 752
0.80(0.67–0.95)
P = 0.011
ischaemic stroke, n = 11 467
0.80(0.66–0.98)
P = 0.029

Per 1 SD lower LDL-C, as printed

Further pooled results

Polygenic low-density lipoprotein cholesterol (LDL-C) score vs chronic obstructive pulmonary disease (COPD) hospitalization, COPD exacerbation, upper respiratory tract infection (URTI)

No association

Safety

Respiratory diseases (PCSK9 genetic score (PCSK9-GS) / PCSK9 variant)

ComparisonEstimateP value
PCSK9-GS · COPD hospitalization, n = 6836OR 1.38 (95% CI 1.08–1.76)P = 0.0089
PCSK9-GS · fatal exacerbations in pre-existing COPD, n = 730OR 3.61 (95% CI 1.71–7.60)P = 7.3 × 10-4
PCSK9 variant · acute URTI, meta-analysis with UK Biobankpooled OR 1.87 (CI 1.38–2.54)P = 5.4 × 10-5
PCSK9 variant · self-reported asthmapooled OR 1.17 (CI 1.04–1.30)P = 0.0071

Original publication

PCSK9 genetic variants and risk of vascular and non-vascular diseases in Chinese and UK populations. Eur J Prev Cardiol. Published 10 January 2024. doi:10.1093/eurjpc/zwae009

Summarised from the published abstract; every number is checked against it